Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005593 | 1.00 | SIGMAR1 (0.68) | SIGMAR1POLBMAPK1TRPA1BCHE | |
| SCHEMBL1189292 | 1.00 | SIGMAR1 (0.68) | SIGMAR1POLBMAPK1TRPA1BCHE | |
| SCHEMBL1752567 | 0.89 | SIGMAR1 (0.59) | SIGMAR1POLBMAPK1BCHELMNA | |
| SCHEMBL31127843 | 0.84 | SIGMAR1 (0.63) | SIGMAR1POLBMAPK1BCHEGAA | |
| SCHEMBL536907 | 0.84 | SIGMAR1 (0.63) | SIGMAR1POLBMAPK1BCHEGAA | |
| N-Benzylamphetamine SCHEMBL2451256 | 0.81 | SIGMAR1 (1.00) | SIGMAR1POLBMAPK1LMNATAAR1 | |
| SCHEMBL172633 | 0.81 | SIGMAR1 (0.70) | SIGMAR1POLBMAPK1BCHELMNA | |
| N-Benzylamphetamine SCHEMBL2795222 | 0.81 | SIGMAR1 (1.00) | SIGMAR1POLBMAPK1LMNATAAR1 | |
| N-Benzylamphetamine SCHEMBL2798189 | 0.81 | SIGMAR1 (1.00) | SIGMAR1POLBMAPK1LMNATAAR1 | |
| SCHEMBL13675825 | 0.81 | SIGMAR1 (0.70) | SIGMAR1POLBMAPK1BCHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110183471-B | Piperazine derivative, preparation method and application | 江苏大学 | 2022-02-15 | — | — | CN | claimed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| US-12319679-B2 | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250066313-A1 | Methods of Synthesis of Chiral 3,5-Disubstituted Morpholine Compounds and Intermediates Useful Therein | BEONE MEDICINES I GMBH (CH) | 2025-02-27 | — | — | US | disclosed |
| WO-2024256988-A1 | SMARCA2 DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| EP-4441027-A1 | METHODS OF SYNTHESIS OF CHIRAL 3, 5-DISUBSTITUTED MORPHOLINE COMPOUNDS AND INTERMEDIATES USEFUL THEREIN | BeiGene Switzerland GmbH (CH) | 2024-10-09 | — | — | EP | disclosed |
| CN-118317943-A | Synthesis method of chiral 3, 5-disubstituted morpholine compound and useful intermediate thereof | 百济神州有限公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-4327814-A2 | MORPHOLINYL, PIPERAZINYL, OXAZEPANYL AND DIAZEPANYL O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230406851-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-12-21 | — | — | US | disclosed |
| EP-3891146-B1 | MORPHOLINYL, PIPERAZINYL, OXAZEPANYL AND DIAZEPANYL DERIVATIVES USEFUL AS O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | AMR TECHNOLOGY, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1692085-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | Chiron Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | CHIRON CORPORATION | 2005-11-24 | — | — | US | disclosed |
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHIRON CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2005-09-15 | — | — | US | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005047244-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | SIGMAR1 4462/4885POLB 2547/4885MAPK1 111/4885 |
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHEK1, CHEK2, RAD1 | SIGMAR1 4811/4885POLB 253/4885MAPK1 398/4885 |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | FGFR3, FGFR1, FGFR2 | SIGMAR1 4880/4885POLB 4810/4885MAPK1 510/4885 |
| US-20230406851-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | SIGMAR1 2026/4885POLB 2726/4885MAPK1 2046/4885 |
| US-12319679-B2 | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | MAN2A1, MAN2B2, MGAT3 | SIGMAR1 2022/4885POLB 3038/4885MAPK1 2547/4885 |
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | SIGMAR1 834/4885POLB 1879/4885MAPK1 4306/4885 |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, PBRM1 | SIGMAR1 1105/4885POLB 2662/4885MAPK1 3484/4885 |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | SIGMAR1 3209/4885POLB 708/4885MAPK1 2918/4885 |
| US-20250066313-A1 | Methods of Synthesis of Chiral 3,5-Disubstituted Morpholine Compounds and Intermediates Useful Therein | BAD, BID, AIFM1 | SIGMAR1 2275/4885POLB 322/4885MAPK1 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.